The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Identification of new epilepsy treatments: Issues in preclinical methodology
Open accessAbstract
Summary: Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for: (1) new symptomatic antiseizure treatments for drug‐resistant seizures with improved efficacy/tolerability profiles, (2) disease‐modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age‐ or gender‐specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug‐resistant seizures, epileptogenesis, and comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888 · cited 1×
“…of preclinical data for compounds progressing from academic laboratories to industrial development programs and, ultimately, to clinical trials (Stroke Therapy Academic Industry Roundtable [STAIR], 1999, Ioannidis, 2005; Benatar, 2007; Fisher et al., 2009; Mullard, 2011; Prinz et al., 2011).”
BackgroundHow common are the "common" neurologic disorders?
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., & Zalutsky, R. (2007) · Neurology · doi:10.1212/01.wnl.0000252807.38124.a3 · Cited by 1,365
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
(1999) · Stroke · doi:10.1161/01.str.30.12.2752 · Cited by 1,251
HOW COMMON ARE THE “COMMON” NEUROLOGIC DISORDERS?
Kaplin, A. I., & Williams, M. (2007) · Neurology · doi:10.1212/01.wnl.0000278071.91524.4d · Cited by 1,131
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Self-citationNeurological Disorders: Public Health Challenges
Vardi, G., & Merrick, J. (2008) · Journal of Policy and Practice in Intellectual Disabilities · doi:10.1111/j.1741-1130.2007.00143.x · Cited by 762
Mechanisms of epileptogenesis and potential treatment targets
Pitkänen, A., & Lukasiuk, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70310-0 · Cited by 614
Self-citationModern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
Self-citationModels of Seizures and Epilepsy
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-088554-1.x5000-2 · Cited by 561
Lux, A. L., Edwards, S. W., Hancock, E., Johnson, A. L., Kennedy, C. R., Newton, R. W., O'Callaghan, F. J., Verity, C. M., & Osborne, J. P. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70199-x · Cited by 405
Development of Spontaneous Recurrent Seizures after Kainate-Induced Status Epilepticus
Williams, P. A., White, A. M., Clark, S., Ferraro, D. J., Swiercz, W., Staley, K. J., & Dudek, F. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0980-08.2009 · Cited by 367
Self-citationLost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Development of new antiepileptic drugs: challenges, incentives, and recent advances
Perucca, E., French, J., & Bialer, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70215-6 · Cited by 339
Self-citationJóźwiak, S., Kotulska, K., Domańska-Pakieła, D., Łojszczyk, B., Syczewska, M., Chmielewski, D., Dunin-Wąsowicz, D., Kmieć, T., Szymkiewicz-Dangel, J., Kornacka, M., et al. (2011) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2011.03.010 · Cited by 310
Epileptogenesis Provoked by Prolonged Experimental Febrile Seizures: Mechanisms and Biomarkers
Dubé, C. M., Ravizza, T., Hamamura, M., Zha, Q., Keebaugh, A., Fok, K., Andres, A. L., Nalcioglu, O., Obenaus, A., Vezzani, A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0551-10.2010 · Cited by 279
Buckmaster, P. S., Ingram, E. A., & Wen, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4179-08.2009 · Cited by 230
Self-citationPreclinical Development of Antiepileptic Drugs: Past, Present, and Future Directions
White, H. S. (2003) · Epilepsia · doi:10.1046/j.1528-1157.44.s7.10.x · Cited by 212
Self-citationMarsh, E., Fulp, C., Gomez, E., Nasrallah, I., Minarcik, J., Sudi, J., Christian, S. L., Mancini, G., Labosky, P., Dobyns, W., et al. (2009) · Brain · doi:10.1093/brain/awp107 · Cited by 209
Posttraumatic epilepsy after controlled cortical impact injury in mice
Hunt, R. F., Scheff, S. W., & Smith, B. N. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2008.10.005 · Cited by 206
Price, M. G., Yoo, J. W., Burgess, D. L., Deng, F., Hrachovy, R. A., Frost, J. D., & Noebels, J. L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0915-09.2009 · Cited by 191
Self-citationHigh-frequency oscillations in epileptic brain
Bragin, A., Engel, J., & Staba, R. J. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283373ac8 · Cited by 188
Self-citationDiscovery of Antiepileptic Drugs
Smith, M., Wilcox, K. S., & White, H. S. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.009 · Cited by 177
Self-citationMasking epilepsy by combining two epilepsy genes
Glasscock, E., Qian, J., Yoo, J. W., & Noebels, J. L. (2007) · Nature Neuroscience · doi:10.1038/nn1999 · Cited by 174
Self-citationTherapeutic approaches to epileptogenesis—Hope on the horizon
Pitkänen, A. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02602.x · Cited by 167
Self-citationPhenomenology of prolonged febrile seizures: Results of the FEBSTAT study
Shinnar, S., Hesdorffer, D. C., Nordli, D. R., Pellock, J. M., O’Dell, C., Lewis, D. V., Frank, L. M., Moshé, S. L., Epstein, L. G., Marmarou, A., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000310774.01185.97 · Cited by 167
Baillie, T. A., & Rettie, A. E. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-089 · Cited by 160
Model of infantile spasms induced by N‐methyl‐ D ‐aspartic acid in prenatally impaired brain
Velı́šek, L., Jehle, K., Asche, S., & Velı́šková, J. (2007) · Annals of Neurology · doi:10.1002/ana.21082 · Cited by 150
Curing epilepsy: Progress and future directions
Jacobs, M. P., Leblanc, G. G., Brooks‐Kayal, A. R., Jensen, F. E., Lowenstein, D. H., Noebels, J. L., Spencer, D. D., & Swann, J. W. (2009) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2009.02.036 · Cited by 148
Self-citationA pulse rapamycin therapy for infantile spasms and associated cognitive decline
Raffo, E., Coppola, A., Ono, T., Briggs, S. W., & Galanopoulou, A. S. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.021 · Cited by 142
Self-citationA model of symptomatic infantile spasms syndrome
Scantlebury, M. H., Galanopoulou, A. S., Chudomelova, L., Raffo, E., Betancourth, D., & Moshé, S. L. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.011 · Cited by 140
Self-citationDyhrfjeld‐Johnsen, J., Berdichevsky, Y., Swiercz, W. B., Sabolek, H. R., & Staley, K. J. (2010) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0b013e3181fe0709 · Cited by 131
Self-citationElectroconvulsive Thresholds of Inbred Mouse Strains
Frankel, W. N., Taylor, L. J., Beyer, B. J., Tempel, B. L., & White, H. S. (2001) · Genomics · doi:10.1006/geno.2001.6564 · Cited by 129
Self-citationSteward, O., Sharp, K., Yee, K. M., & Hofstadter, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.12.010 · Cited by 124
Rakhade, S. N., Klein, P., Huynh, T., Hilario‐Gomez, C., Kosaras, B., Rotenberg, A., & Jensen, F. E. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02992.x · Cited by 120
Faingold, C. L., Tupal, S., & Randall, M. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.06.015 · Cited by 106
A new animal model of infantile spasms with unprovoked persistent seizures
Lee, C. L., Frost, J. D., Swann, J. W., & Hrachovy, R. A. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01377.x · Cited by 105
A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model
Pinzón, A., Marcillo, A. E., Quintana, A., Stamler, S., Bunge, M. B., Bramlett, H. M., & Dietrich, W. D. (2008) · Brain Research · doi:10.1016/j.brainres.2008.09.047 · Cited by 102
Infantile Spasms and Down Syndrome: A New Animal Model
Cortez, M. A., Shen, L., Wu, Y., Aleem, I. S., Trepanier, C. H., Sadeghnia, H. R., Ashraf, A., Kanawaty, A., Liu, C.-C., Stewart, L. S., et al. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e31819d9076 · Cited by 99
Reliability of 'new drug target' claims called into question
Mullard, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3545 · Cited by 99
Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke
Papadopoulos, S. M., Chandler, W. F., Salamat, M. S., Topol, E. J., & Sackellares, J. C. (1987) · Journal of neurosurgery · doi:10.3171/jns.1987.67.3.0394 · Cited by 97
Kharatishvili, I., & Pitkänen, A. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.03.007 · Cited by 82
Self-citationBiomarkers in Epilepsy: Introduction
Engel, J. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.62 · Cited by 70
Self-citationDevelopmental impact of a familial GABAA receptor epilepsy mutation
Chiu, C. H., Reid, C. A., Tan, H. O., Davies, P. J., Single, F. N., Koukoulas, I., Berkovic, S. F., Tan, S., Sprengel, R., Jones, M. V., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21440 · Cited by 66
Mechanisms of drug resistance in status epilepticus
Löscher, W. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01357.x · Cited by 62
Self-citationProgress in epilepsy: reducing the treatment gap and the promise of biomarkers
Engel, J. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282f4edc3 · Cited by 59
Self-citationLife After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post–NXY-059 Era
Ginsberg, M. D. (2007) · Stroke · doi:10.1161/strokeaha.106.479170 · Cited by 57
Role of Tissue Plasminogen Activator in Acute Ischemic Stroke
Hatcher, M. A., & Starr, J. A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p525 · Cited by 38
When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy
Perucca, E. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02589.x · Cited by 31
Self-citationMultiparametric ISODATA analysis of embolic stroke and rt-PA intervention in rat
Ding, G., Jiang, Q., Zhang, L., Zhang, Z., Knight, R. A., Hamid Soltanian-zadeh, A., Lü, M., Ewing, J. R., Li, Q., Whitton, P. A., et al. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.017 · Cited by 30
Posttraumatic epilepsy induced by lateral fluid-percussion brain injury in rats
Pitkänen, A., Kharatishvili, I., Nissinen, J., & McIntosh, T. (2006) · Elsevier eBooks · doi:10.1016/b978-012088554-1/50039-6 · Cited by 20
Self-citationGoodkin, H. P., & Kapur, J. (2003) · Epiliepsy currents/Epilepsy currents · doi:10.1046/j.1535-7597.2003.03104.x · Cited by 20
Cited by
Moshé, S. L., Perucca, E., Ryvlin, P., & Tomson, T. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60456-6 · Cited by 905
Self-citationAstrocytes: a central element in neurological diseases
Pekny, M., Pekna, M., Messing, A., Steinhäuser, C., Lee, J.-M., Parpura, V., Hol, E. M., Sofroniew, M. V., & Verkhratsky, A. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1513-1 · Cited by 755
Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction
Goldberg, E. M., & Coulter, D. A. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3482 · Cited by 542
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy
Wykes, R. C., Heeroma, J. H., Mantoan, L., Zheng, K., MacDonald, D. C., Deisseroth, K., Hashemi, K. S., Walker, M. C., Schorge, S., & Kullmann, D. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004190 · Cited by 272
Metadata
- Authors
- Galanopoulou, A. S., Buckmaster, P. S., Staley, K. J., Moshé, S. L., Perucca, E., Engel, J., Löscher, W., Noebels, J. L., Pitkänen, A., Stables, J., White, H. S., O’Brien, T. J., & Simonato for the American Epilepsy Society Basic Science Com, M.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2012-01-31
- Volume
- 53
- Issue
- 3
- Pages
- 571-582
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1492931325
- Cited by
- 261
- References
- 55
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.